Sistemic will be attending Phacilitate Cell & Gene Therapy World and the World Stem Cell Summit

Release Date: January 17, 2018

GLASGOW, SCOTLAND Sistemic will be attending Phacilitate Cell & Gene Therapy World and the World Stem Cell Summit in January to highlight the development of their assay for assessment of pluripotent stem cell contamination in derived cell therapy products

Sistemic Ltd. is excited to announce that they will be attending both Phacilitate Cell & Gene Therapy World and the World Stem Cell Summit in January in Miami to highlight the development of their miRNA-based assay for the assessment of residual pluripotent stem cell contamination in derived cell therapy products - SistemPSCCheck™ - as well as other products in the SistemCheck™ range. The development of SistemPSCCheck™ is being undertaken in conjunction with LGC, the UK National Measurement Laboratory and Designated Institute for chemical and bio-measurement. The work at Sistemic is being supported by the UK’s innovation agency, Innovate UK, under the “Analysis for Innovators” grant. PR image
Sistemic will be presenting at Phacilitate Cell & Gene Therapy World, giving an overview of the developed assay on Tuesday 24th January 4.00-5.30pm and will also be hosting a roundtable discussion on “The Challenges of Contamination Assessment in iPSC Derived Cell Therapy Products” at the WSCS on Thursday 25th January 1.15-2.15pm. Please join us for both of these events.
Jim Reid, CEO stated "This is a critical milestone for the company representing the first productization of our IP portfolio. The iPSC field holds great promise but without products like SistemPSCCheck™ the necessary controls over manufacturability will not enable the sector to provide the undoubted revolutionary treatments that are possible. On the back of our recent successful funding round, Sistemic is perfectly set for rapid growth in 2018.”
David Mallinson, VP of Scientific Operations added "We are delighted to be able to present at Phacilitate Cell & Gene Therapy World and WSCS to give an overview of the development of the assay. The developed assay has great promise and the potential to facilitate the clinical progress of pluripotent stem cell-derived cell therapy products, allowing them to be developed to safer clinical products more quickly"
Potential partners interested in receiving further information on the availability of the test or to be part of an Early Access Programme should contact press@sistemic.co.uk

Sistemic
Sistemic’s primary business is focused on providing innovative microRNA-based problem-solving services and kit-based products to areas of unmet need within Pharmaceutical, Biotechnology and the Cell and Gene Therapy research, development and manufacture markets. MicroRNAs are seen as the master controllers of a cell and as such Sistemic believe that they are providing instructive information on effects on a whole cell or organism rather than an isolated pathway. This system approach means that the data produced is more indicative of the biology and more diagnostic of actual effect. Their extensive suite of tools for the Cell Therapy community includes SistemQC™ which is used to characterise cells including stem cells (Cell Identity, Purity, Potency, and Safety) as well as monitoring the QC of production. Furthermore, cell products in the later stages of clinical development benefit from SistemQC™ miRNA-based profiling approach in facilitating patient stratification and monitoring the response to the treatment. In addition, the drug development markets are served through a range of products which include SistemTOX™, SistemKB™ and SistemRNA™. Sistemic has a worldwide customer base and a strong intellectual property portfolio.

For more information contact: press@sistemic.co.uk

LGC

LGC is an international life sciences measurement and testing company with leading positions in growing markets. LGC provides a range of measurement products and services which underpin the safety, health and security of the public, including reference materials and proficiency testing, genomics reagents and instrumentation, and expert sample analysis and interpretation. LGC serves customers across a number of end markets including Pharmaceuticals, Agricultural Biotechnology, Diagnostics, Food, Environment, Government and Academia.
LGC’s headquarters are in London and the company employs over 2,600 people, operating out of 22 countries worldwide. Its operations are extensively accredited to international quality standards such as ISO/IEC 17025, ISO 13485, ISO 9001, GMP, GLP and ISO Guide 34.
With a history dating back to 1842, LGC has been home to the UK Government Chemist for more than 100 years and is the UK National Measurement Laboratory and Designated Institute for chemical and bio measurement. LGC was privatised in 1996 and is now owned by funds affiliated with KKR. 
For more information, please visit www.lgcgroup.com